Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis

Kemal Erol1, Ragıp Ertaş2

1Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Kayseri City Hospital, Kayseri, Turkey
2Department of Dermatology, Kayseri City Hospital, Kayseri, Turkey

Keywords: Paradoxical, psoriasis, rheumatoid arthritis, tofacitinib

Abstract

Paradoxical psoriasis or psoriasiform lesion is an adverse effect, represented by the occurrence of a psoriasiform lesion or exacerbation of psoriasis caused by the drugs normally used for the management of psoriasis. In this article, we present the first case of a 45-year-old male patient with rheumatoid arthritis who developed psoriasiform lesions following treatment with tofacitinib, and highlight the possible pathogenetic mechanisms involved in such an occurrence.

Citation: Erol K, Ertaş R. Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis. Arch Rheumatol 2020;35(3):440-442.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.